MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

CorMedix Company Profile (NYSEMKT:CRMD)

Consensus Ratings for CorMedix (NYSEMKT:CRMD) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $5.63

Analysts' Ratings History for CorMedix (NYSEMKT:CRMD)
Show:
DateFirmActionRatingPrice TargetActions
5/16/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016Rodman & RenshawBoost Price TargetBuy$6.50 -> $7.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015Roth CapitalLower Price TargetNeutral$2.75 -> $2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2015HC WainwrightInitiated CoverageBuy$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for CorMedix (NYSEMKT:CRMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/5/2016Q1($0.09)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.12)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2014($0.09)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/20/2014($0.13)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for CorMedix (NYSEMKT:CRMD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for CorMedix (NYSEMKT:CRMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for CorMedix (NYSEMKT:CRMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016Antony PfaffleInsiderSell29,657$2.14$63,465.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Antony PfaffleInsiderSell10,000$2.16$21,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Antony PfaffleInsiderSell4,900$2.21$10,829.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Antony PfaffleInsiderSell5,443$2.27$12,355.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Antony PfaffleInsiderSell10,000$2.38$23,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Matthew DuffyDirectorSell46,106$2.73$125,869.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Steven W LefkowitzDirectorSell50,000$2.88$144,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Cora M TellezDirectorBuy8,600$2.90$24,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Antony PfaffleInsiderSell15,000$2.89$43,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Steven W LefkowitzDirectorSell30,000$2.93$87,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Antony PfaffleInsiderSell12,300$2.82$34,686.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Antony PfaffleInsiderSell60,000$2.68$160,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015Randy MilbyCEOBuy1,610$3.88$6,246.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Taunia MarkvickaDirectorBuy4,000$4.81$19,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Randy MilbyCEOBuy1,245$5.02$6,249.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Matthew DuffyDirectorSell30,000$6.48$194,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Randy MilbyCEOBuy1,026$6.09$6,248.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Randy MilbyCEOBuy1,211$5.16$6,248.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Randy MilbyCEOBuy1,911$3.27$6,248.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2015Randy MilbyCEOBuy2,016$3.10$6,249.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Randy MilbyCEOBuy4,734$1.32$6,248.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Randy MilbyCEOBuy4,464$1.40$6,249.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Cora M TellezDirectorBuy11,086$1.52$16,850.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Randy MilbyCEOBuy4,111$1.52$6,248.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2014Randy MilbyCEOBuy3,434$1.82$6,249.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Randy MilbyCEOBuy3,324$1.88$6,249.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Randy MilbyCEOBuy3,654$1.71$6,248.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Randy MilbyCEOBuy3,125$2.00$6,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Randy MilbyCEOBuy3,140$1.99$6,248.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Randy MilbyCEOBuy6,250$2.00$12,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Randy MilbyCEOBuy2,732$1.83$4,999.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Steven W LefkowitzInsiderBuy18,000$0.78$14,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for CorMedix (NYSEMKT:CRMD)
DateHeadline
06/25/16 03:17 PMAnalysts Observable Stocks: CorMedix Inc (NYSEMKT:CRMD) , AxoGen, Inc. (NASDAQ:AXGN) - Street Updates
06/22/16 08:39 PMInterim Chief Medical Officer of CorMedix Inc (NYSEMKT:CRMD), Pfaffle Antony, sells 10,000 shares worth $21,569
06/22/16 03:33 PMMorning Watch List: CorMedix, Inc. (NYSEMKT:CRMD), Health Insurance Innovations, Inc. (NASDAQ:HIIQ), Gladstone ... - KC Register
06/22/16 03:33 PMRecently Issued Stock Ratings For CorMedix Inc (CRMD) - Fiscal Standard
06/19/16 03:12 PMThis Weeks Broker Views For CorMedix Inc (CRMD) - Fiscal Standard
06/14/16 03:17 PMCorMedix Inc. (CRMD) - Financial and Strategic SWOT Analysis Review - New Market Study Published
06/14/16 03:17 PMInterim Chief Medical Officer of CorMedix Inc (NYSEMKT:CRMD), Pfaffle Antony, sells 10,000 shares worth $23,789
06/13/16 10:55 AMWatch List: Pandora Media Inc (NYSE:P), CorMedix, Inc. (NYSEMKT:CRMD), Twitter Inc (NYSE:TWTR), Brookfield ... - KC Register
06/13/16 07:31 AMCorMedix Inc. Announces Publication of Pharmacoeconomic Study that Highlights the Clinical and Economic Need for Products that Can Prevent Catheter-Related Bloodstream Infections - [Accesswire] - Data Published in the Journal of Critical Care Supports the Potential of Neutrolin® as a Non-antibiotic Antimicrobial Solution BEDMINSTER, NJ / ACCESSWIRE / June 13, 2016 / CorMedix Inc. (NYSE MKT: CRMD), ...
06/08/16 01:16 PMETF’s with exposure to CorMedix, Inc. : June 8, 2016 -
06/03/16 03:35 PMCorMedix Inc (CRMD) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/03/16 03:35 PMCorMedix Inc (CRMD) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/02/16 09:27 PMA Director at Cormedix Inc (NYSE MKT: CRMD) is Selling Shares - Analyst Ratings - A Director at Cormedix Inc (NYSE MKT: CRMD) is Selling SharesAnalyst RatingsToday, a Director at Cormedix Inc (NYSE MKT: CRMD), Steven W. Lefkowitz, sold shares of CRMD for $144k. In addition to Steven W. Lefkowitz, 10 other CRMD executives reported Sell trades in the last month. The company has a one year high of $7.38 and ...CorMedix Inc (CRMD) Updated Broker RatingsRisers & FallersCorMedix Inc. (CRMD) Director Sells $144000.00 in StockLet Me Know About ThisIs CorMedix Inc. (NYSEMKT:CRMD) Stock a Sell after Steven Lefkowitz's Insider Sale?Franklin IndependentMarket Digestall 5 news articles »
06/02/16 03:31 PMLefkowitz Steven W, Director of CorMedix Inc (NYSEMKT:CRMD) sells 7,800 shares - According to CorMedix Inc's most recent Form 4 filing with the SEC dated Jun 01 04:24 PM, company Director, Lefkowitz Steven W disclosed selling 7,800 shares at a cost of $3.04. At the time of this transaction (May 27), this trade was worth $23,727 in total.
06/02/16 10:56 AMCorMedix Inc. (CRMD) Director Sells $144000.00 in Stock - Let Me Know About This - CorMedix Inc. (CRMD) Director Sells $144000.00 in StockLet Me Know About ThisCorMedix logo CorMedix Inc. (NYSEMKT:CRMD) Director Steven W. Lefkowitz sold 50,000 shares of the business's stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $2.88, for a total transaction of $144,000.00.A Director at Cormedix Inc (NYSE MKT: CRMD) is Selling SharesAnalyst RatingsIs CorMedix Inc. (NYSEMKT:CRMD) Stock a Sell after Steven Lefkowitz's Insider Sale?Franklin Independentall 4 news articles »
05/30/16 10:45 PMAfter Last Week What Do Analysts Think Of CorMedix Inc (CRMD) - Share Trading News - After Last Week What Do Analysts Think Of CorMedix Inc (CRMD)Share Trading News07/28/2014 – CorMedix Inc was downgraded to “neutral” by analysts at Zacks. They now have a USD 2.2 price target on the stock. The share price of CorMedix Inc (CRMD) was down -6.29% during the last trading session, with a day high of 3.10. 396351 ...
05/28/16 10:50 AMTellez Cora M, Director of CorMedix Inc (NYSEMKT:CRMD) buys 8,600 shares - According to CorMedix Inc's most recent Form 4 filing with the SEC dated May 26 04:14 PM, company Director, Tellez Cora M disclosed buying 8,600 shares at a cost of $2.90. At the time of this transaction (May 25), this trade was worth $24,940 in total.
05/26/16 11:01 AMLatest Analyst Ratings For CorMedix Inc (CRMD) - Share Trading News - Latest Analyst Ratings For CorMedix Inc (CRMD)Share Trading NewsCorMedix Inc has a 50 day moving average of 3.54 and a 200 day moving average of 2.45. The stock's market capitalization is 98.36M, it has a 52-week low of 1.15 and a 52-week high of 7.38. The share price of the company (CRMD) was down -4.21%, with a ...Cormedix Inc. (CRMD) Files Form 4 Insider Selling : Steven W Lefkowitz Sells 30000 SharesMarket DigestCormedix Incorporated (NYSEMKT:CRMD) Short Interest Decreased By 2.01%Wall Street Hints and Newsall 4 news articles »
05/26/16 11:01 AMThe Interim Chief Medical Officer of Cormedix Inc (NYSE MKT: CRMD) is Selling Shares - Analyst Ratings - The Interim Chief Medical Officer of Cormedix Inc (NYSE MKT: CRMD) is Selling SharesAnalyst RatingsToday, the Interim Chief Medical Officer of Cormedix Inc (NYSE MKT: CRMD), Antony Pfaffle, sold shares of CRMD for $34.61k. Over the last month, Antony Pfaffle has reported 7 Sell trades on CRMD for a total of $306.4k. In addition to Antony Pfaffle ...The Insider Antony Pfaffle Unloaded 12700 shares of CorMedix Inc. (NYSEMKT:CRMD)Wall Street Hints and NewsCormedix Inc. (CRMD) Files Form 4 Insider Selling : Antony Pfaffle Sells 12700 SharesMarket Digestall 3 news articles »
05/26/16 07:05 AMCorMedix Inc. to Present at 2016 Marcum MicroCap Conference - [Accesswire] - BEDMINSTER, NJ / ACCESSWIRE / May 26, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of ...
04/12/16 01:06 PMCorMedix To Present Data From Neutrolin Usage Monitoring Program On May 23 - CorMedix Inc. (NYSE: CRMD) disclosed that its Professor of Medicine and Director of Nephrology, would deliver a oral presentation. The title was "A Novel Taurolidine Containing Catheter Lock Solution CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a ...Full story available on Benzinga.com
01/28/16 08:00 AMThe Life Sciences Report's 2016 Small-Cap Biotech Watchlist - [Marketwired] - This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies ...
01/21/16 07:05 AMCorMedix to Present at National Kidney Foundation® 2016 Spring Clinical Meetings - [PR Newswire] - BEDMINSTER, N.J., Jan. 21, 2016 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that an clinical abstract highlighting key data from the Company's landmark post-approval surveillance study has been accepted for publication in the peer-reviewed American Journal of Kidney Diseases, and will be presented as a poster during the National Kidney Foundation® 2016 Spring Clinical Meetings, held April 27 – May 1, 2016, in Boston, Massachusetts. The Neutrolin® Usage Monitoring Program (NUMP) examined the use of CorMedix's commercialized product in Europe, Neutrolin, an anti-infective solution for the prevention of catheter-related blood infections and thrombosis, which are the major complications observed in patients undergoing hemodialysis. The results to be published compare the reduced rates of these catheter-related complications with routine use of Neutrolin as a novel catheter lock solution versus historical benchmark rates.
01/19/16 03:07 PMCORMEDIX INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
About CorMedix

CorMedix logoCorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: CRMD
  • CUSIP:
Key Metrics:
  • Previous Close: $1.91
  • 50 Day Moving Average: $2.61
  • 200 Day Moving Average: $2.46
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $68.82M
  • Current Quarter EPS Consensus Estimate: $-0.52 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha